Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier

BACKGROUND: Molnupiravir is an orally bioavailable prodrug of the nucleoside analogue β-D-N4-hydroxycytidine (NHC) and is used to treat coronavirus disease 2019 (COVID-19). However, the pharmacokinetics and transplacental transfer of molnupiravir in pregnant women are still not well understood. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chun-Hao, Peng, Wen-Ya, Lee, Wan-Hsin, Lin, Tung-Yi, Yang, Muh-Hwa, Dalley, Jeffrey W., Tsai, Tung-Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427982/
https://www.ncbi.nlm.nih.gov/pubmed/37544201
http://dx.doi.org/10.1016/j.ebiom.2023.104748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427982/
https://www.ncbi.nlm.nih.gov/pubmed/37544201
http://dx.doi.org/10.1016/j.ebiom.2023.104748

Ejemplares similares